[go: up one dir, main page]

DE60141773D1 - Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren - Google Patents

Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren

Info

Publication number
DE60141773D1
DE60141773D1 DE60141773T DE60141773T DE60141773D1 DE 60141773 D1 DE60141773 D1 DE 60141773D1 DE 60141773 T DE60141773 T DE 60141773T DE 60141773 T DE60141773 T DE 60141773T DE 60141773 D1 DE60141773 D1 DE 60141773D1
Authority
DE
Germany
Prior art keywords
ligands
use process
similar receptor
great
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60141773T
Other languages
English (en)
Inventor
Alan Aderem
Fumitaka Hayashi
David M Underhill
Adrian Ozinsky
Kelly D Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Systems Biology
Original Assignee
Institute for Systems Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23094403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60141773(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Institute for Systems Biology filed Critical Institute for Systems Biology
Application granted granted Critical
Publication of DE60141773D1 publication Critical patent/DE60141773D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60141773T 2001-04-20 2001-07-20 Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren Expired - Lifetime DE60141773D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28547701P 2001-04-20 2001-04-20
PCT/US2001/022978 WO2002085933A1 (en) 2001-04-20 2001-07-20 Toll-like receptor 5 ligands and methods of use

Publications (1)

Publication Number Publication Date
DE60141773D1 true DE60141773D1 (de) 2010-05-20

Family

ID=23094403

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60141773T Expired - Lifetime DE60141773D1 (de) 2001-04-20 2001-07-20 Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren

Country Status (5)

Country Link
US (3) US7915381B2 (de)
EP (1) EP1379552B2 (de)
AT (1) ATE463505T1 (de)
DE (1) DE60141773D1 (de)
WO (1) WO2002085933A1 (de)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US8703146B2 (en) 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
WO2002085933A1 (en) 2001-04-20 2002-10-31 The Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
WO2004022092A2 (en) * 2002-09-03 2004-03-18 Fondation Eurovacc Flagellin peptides as adjuvants for vaccines
EP1599726A4 (de) * 2003-02-27 2009-07-22 3M Innovative Properties Co Selektive modulation von tlr-vermittelter biologischer aktivität
WO2004094671A2 (en) * 2003-04-22 2004-11-04 Coley Pharmaceutical Gmbh Methods and products for identification and assessment of tlr ligands
EP1617845A4 (de) * 2003-04-28 2006-09-20 3M Innovative Properties Co Zusammensetzungen und verfahren zur induktion von opioid-rezeptoren
TW200510412A (en) * 2003-08-12 2005-03-16 3M Innovative Properties Co Oxime substituted imidazo-containing compounds
AR045529A1 (es) * 2003-08-27 2005-11-02 3M Innovative Properties Co Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi
CA2537763A1 (en) * 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
WO2005032484A2 (en) * 2003-10-03 2005-04-14 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
WO2005040208A2 (en) * 2003-10-21 2005-05-06 Androclus Therapeutics, Soa Peptides derived from heat shock proteins binding toll-like receptors 2 and 4 and their use
EP1689433B1 (de) 2003-10-22 2010-06-30 ID Biomedical Corporation of Quebec Zusammensetzungen und verfahren zur aktivierung der eigenen und allergischen immunität
EP1682544A4 (de) * 2003-11-14 2009-05-06 3M Innovative Properties Co Hydroxylaminsubstituierte imidazo-ringverbindungen
JP2007511527A (ja) 2003-11-14 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー オキシム置換イミダゾ環化合物
AU2004293078B2 (en) * 2003-11-25 2012-01-19 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8802853B2 (en) * 2003-12-29 2014-08-12 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
EP1699788A2 (de) * 2003-12-30 2006-09-13 3M Innovative Properties Company Imidazochinolinyl-, imidazopyridinyl- und imidazonaphthyridinylsulfonamide
KR20050073865A (ko) 2004-01-12 2005-07-18 대한민국(전남대학교총장) 비브리오 패혈증균 편모 구성인자 플라젤린을유효성분으로 함유하는 백신 보조제
EP1730143A2 (de) * 2004-03-24 2006-12-13 3M Innovative Properties Company Amidsubstituierte imidazopyridine, imidazochinoline und imidazonaphthyridine
EP1755668A2 (de) * 2004-05-07 2007-02-28 Hans-Gustaf Ljunggren Adjuvantien
DE102004024674A1 (de) * 2004-05-18 2005-12-15 Wolfgang Lorenz Mittel und Verfahren zur Diagnose, Prophylaxe und Therapie von Bindegewebserkrankungen
US8017779B2 (en) * 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006065280A2 (en) * 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US7897609B2 (en) * 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8026366B2 (en) * 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US20070259881A1 (en) * 2004-06-18 2007-11-08 Dellaria Joseph F Jr Substituted Imidazo Ring Systems and Methods
US20090137390A1 (en) * 2004-06-30 2009-05-28 Eric Wendell Triplett Materials and methods for enhancing nitrogen fixation in plants
US20090270443A1 (en) * 2004-09-02 2009-10-29 Doris Stoermer 1-amino imidazo-containing compounds and methods
WO2006039701A1 (en) * 2004-10-01 2006-04-13 University Of South Florida Flagellin-based adjuvants and vaccines
US20110070575A1 (en) * 2004-12-08 2011-03-24 Coley Pharmaceutical Group, Inc. Immunomodulatory Compositions, Combinations and Methods
JP5094407B2 (ja) * 2004-12-16 2012-12-12 ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ Ｙｅｒｓｉｎｉａｐｅｓｔｉｓの免疫療法におけるフラジェリンの使用
US8007812B2 (en) 2004-12-22 2011-08-30 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
HU227285B1 (en) * 2004-12-29 2011-01-28 Mta Enzimologiai Intezet Modified flagellins and flagellar filaments useful as receptors and processes for producing same
AU2005322898B2 (en) * 2004-12-30 2011-11-24 3M Innovative Properties Company Chiral fused (1,2)imidazo(4,5-c) ring compounds
WO2006083440A2 (en) 2004-12-30 2006-08-10 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
AR052195A1 (es) * 2005-01-19 2007-03-07 Vaxinnate Corp Composiciones de patrones moleculares asociados a patogenos en metodos de uso
WO2006084251A2 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
JPWO2006085411A1 (ja) * 2005-02-10 2008-06-26 国立大学法人 北海道大学 免疫応答を惹起するための新規アジュバントおよびその利用
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
US7700728B2 (en) * 2005-03-24 2010-04-20 Schering Corporation Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell receptors
WO2006107853A2 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
CA2602590A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
DE102005020798A1 (de) * 2005-04-28 2006-11-02 Eberhard-Karls-Universität Tübingen Universitätsklinikum Verwendung von TLR- und/oder Nod2-Liganden zur Herstellung eines Arzneimittels zur Behandlung einer Krankheit des zentralen Nervensystems
KR100804507B1 (ko) 2005-05-17 2008-02-20 전남대학교산학협력단 플라젤린을 포함하는 천식 및 알레르기 질환 면역치료제
US8137930B2 (en) * 2005-10-28 2012-03-20 University Of Maryland, Baltimore Attenuated Salmonella enterica serovar paratyphi A and uses thereof
WO2007062043A1 (en) * 2005-11-23 2007-05-31 Coley Pharmaceutical Group Inc. Method of activating murine toll-like receptor 8
US8889149B2 (en) * 2006-02-16 2014-11-18 Wayne State University Use of flagellin to prevent and treat gram negative bacterial infection
TW200745158A (en) 2006-03-07 2007-12-16 Vaxinnate Corp Compositions that include hemagglutinin, methods of making and methods of use thereof
US7906506B2 (en) * 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
EP2097094A4 (de) * 2006-11-01 2011-01-05 George Mason Intellectual Prop Biomarker für neurologische leiden
WO2008097016A1 (en) * 2007-02-09 2008-08-14 Chonnam National University Modified flagellin improved toll-like receptor 5 stimulating activity
US20100330190A1 (en) * 2007-12-17 2010-12-30 Compans Richard W Immunogenic compositions and methods of use thereof
WO2009082440A2 (en) * 2007-12-18 2009-07-02 Vaxinnate Corporation Compositions of toll-like receptor agonists and malaria antigens and methods of use
JP2011519828A (ja) 2008-04-18 2011-07-14 バクシネート コーポレーション フラジェリンの欠失変異体と使用方法
CA2732763A1 (en) 2008-08-01 2010-02-04 Cleveland Biolabs, Inc. Methods for treating reperfusion injuries
US8486408B2 (en) * 2008-10-03 2013-07-16 Emory University Methods for the treatment of graft-versus-host disease
WO2010080007A2 (ko) * 2009-01-09 2010-07-15 부산대학교 산학협력단 Ｔｏｌｌ 유사수용체２ 리간드로서 기능하는 그람양성균 유래의 리포단백질
EP2408475B1 (de) 2009-03-18 2017-11-15 Wake Forest University Health Sciences Flagellin-fusionsproteine und ihre verwendung zur auslösung von immunantworten gegen pseudomonas aeruginosa
WO2010135704A2 (en) * 2009-05-22 2010-11-25 Institute For Systems Biology Secretion-related bacterial proteins for nlrc4 stimulation
WO2010141312A2 (en) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
WO2011028875A1 (en) 2009-09-03 2011-03-10 Wake Forest University Health Sciences Immunogenic conjugates for producing immune responses to drugs of abuse and methods of use
WO2011097573A2 (en) 2010-02-05 2011-08-11 Mount Sinai School Of Medicine Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells
GB2481267B (en) 2010-06-15 2016-04-20 Univ Leicester Assay for determining the risk of a toll-like receptor containing foodstuff for causing systemic inflammation in vivo
CA2800206C (en) 2010-06-25 2018-06-05 (Inserm) Institut National De La Sante Et De La Recherche Medicale Methods and pharmaceutical compositions for the treatment of respiratory tract infections
US9872895B2 (en) 2010-09-24 2018-01-23 Emory University TLR5 ligands, therapeutic methods, and compositions related thereto
US9376473B2 (en) 2011-01-10 2016-06-28 Cleveland Biolabs, Inc. Use of Toll-Like Receptor agonist for treating cancer
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
EP2847215A1 (de) * 2012-05-07 2015-03-18 Synthes GmbH Verfahren und vorrichtungen zur behandlung einer bandscheibenerkrankung
US9296792B2 (en) 2012-05-23 2016-03-29 The Board Of Trustees Of The Leland Stanford Junior University Ordered flagellin array as an immunostimulant
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
GB201306536D0 (en) * 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
ES3020582T3 (en) 2013-07-26 2025-05-23 Inst Nat Sante Rech Med Methods and pharmaceutical compositions for the treatment of bacterial infections
CA2994218A1 (en) 2014-07-30 2016-02-04 Cleveland Biolabs, Inc. Flagellin compositons and uses
WO2016109002A2 (en) 2014-10-16 2016-07-07 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
SI3065748T1 (en) 2014-12-23 2018-05-31 4D Pharma Research Limited Severe bacteroid tethethioomycron and its use in reducing inflammation
SI3193901T1 (en) 2014-12-23 2018-06-29 4D Pharma Research Limited Pirin polypeptide and immune modulation
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
SG10201912326QA (en) 2015-06-15 2020-02-27 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
SI3360559T1 (sl) 2015-06-15 2020-02-28 4D Pharma Research Limited Sestavki, ki vsebujejo bakterijske seve
HRP20191949T1 (hr) 2015-06-15 2020-01-24 4D Pharma Research Limited Blautia stercosis i wexlerae za upotrebu u liječenju upalnih i autoimunih bolesti
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3209310B1 (de) 2015-11-20 2018-01-31 4D Pharma Research Limited Zusammensetzungen mit bakterienstämmen
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
EP3313423B1 (de) 2016-03-04 2019-04-24 4D Pharma Plc Zusammensetzungen mit bakteriellen blautia-stämmen zur behandlung von viszeraler überempfindlichkeit
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
SI3630136T1 (sl) 2017-05-22 2021-08-31 4D Pharma Research Limited Sestave, ki zajemajo bakterijske seve
EP3630942B1 (de) 2017-05-24 2022-11-30 4D Pharma Research Limited Zusammensetzungen mit bakterienstamm
MD3600363T2 (ro) 2017-06-14 2021-05-31 4D Pharma Res Ltd Compoziții cuprinzând tulpini bacteriene
WO2018229236A2 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
SMT202000695T1 (it) 2017-06-14 2021-01-05 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
US10988754B2 (en) 2017-07-04 2021-04-27 Cure Vac AG Nucleic acid molecules
US20200170258A1 (en) 2017-07-20 2020-06-04 Spogen Biotech Inc. Bioactive polypeptides for improvements in plant protection, growth and productivity
US12440536B2 (en) 2018-05-18 2025-10-14 The University Of Hong Kong Compositions of toll-like receptor 5 (TLR5) agonist and methods of use thereof
KR102524577B1 (ko) * 2019-04-22 2023-04-21 전남대학교산학협력단 플라젤린 융합 단백질 및 이의 용도
FR3114970B1 (fr) 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
CN118871092A (zh) 2021-06-30 2024-10-29 Inserm(法国国家健康医学研究院) 用于肺部递送鞭毛蛋白的气雾剂组合物
KR20240022417A (ko) * 2022-08-10 2024-02-20 주식회사 메디스팬 바실러스 서브틸리스 플라젤린 변이체 및 이의 용도
JP2025537485A (ja) * 2022-10-19 2025-11-18 ヘン イ，ジョン Ｔｌｒ５活性能を有するフラジェリン免疫増強剤誘導体の真核細胞発現システムを用いた製造及び応用
WO2025172452A1 (en) 2024-02-14 2025-08-21 Institut National de la Santé et de la Recherche Médicale Combination for treating bacterial infection due to pseudomonas aeruginosa antibiotic-resistant strain
WO2026022365A1 (en) * 2024-07-26 2026-01-29 Elanco Animal Health Gmbh Mammalian il-4/il-13/flagellin constructs

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194254A (en) * 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
US6130082A (en) * 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
US5612035A (en) * 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
KR0162259B1 (ko) * 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
US5618533A (en) * 1992-02-11 1997-04-08 Yale University Flagellin-based polypeptides for the diagnosis of lyme disease
US5888810A (en) * 1993-11-12 1999-03-30 The United States Of America As Represented By The Secretary Of Agriculture Campylobacteri jejuni flagellin-escherichia coli LT-B fusion protein
US5420109A (en) * 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
US5817308A (en) * 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US6030624A (en) * 1996-08-16 2000-02-29 Uab Research Foundation Mucosal immunogens for novel vaccines
US6797813B2 (en) * 1996-09-23 2004-09-28 Schering Corporation AK155 antibodies and binding fragments thereof
EP0930893B1 (de) * 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulierende oligonucleotidekonjugate
JP2002527494A (ja) * 1998-10-16 2002-08-27 ザ・ジェネラル・ホスピタル・コーポレイション 細胞内病原体を標的付ける光増感剤である複合体
ATE349526T1 (de) * 1999-05-25 2007-01-15 Immunex Corp Il-1 eta dna und polypeptide
US6740487B1 (en) * 1999-06-10 2004-05-25 University Of Iowa Research Foundation Variant TLR4 nucleic acid and uses thereof
DE60118359T2 (de) * 2000-04-28 2006-12-07 Immunex Corp., Thousand Oaks Humanische pellino-polypeptide
FR2812304B1 (fr) * 2000-07-31 2004-12-17 Bio Merieux Complexe de lipo-viro-particules, procede de preparation et applications
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
CA2418036A1 (en) * 2000-07-31 2002-02-07 Yale University Innate immune system-directed vaccines
WO2002085933A1 (en) 2001-04-20 2002-10-31 The Institute For Systems Biology Toll-like receptor 5 ligands and methods of use

Also Published As

Publication number Publication date
US20110008318A1 (en) 2011-01-13
WO2002085933A1 (en) 2002-10-31
US7915381B2 (en) 2011-03-29
ATE463505T1 (de) 2010-04-15
US20120269855A1 (en) 2012-10-25
EP1379552B2 (de) 2014-11-19
US20030044429A1 (en) 2003-03-06
US9085616B2 (en) 2015-07-21
EP1379552A1 (de) 2004-01-14
EP1379552B1 (de) 2010-04-07

Similar Documents

Publication Publication Date Title
DE60141773D1 (de) Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
MY125202A (en) Vaccine
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
ATE357930T1 (de) Immunmodulierende zusammensetzungen die eine an antigen gebundene immunstimulierende sequenz enthalten und deren verwendungen
WO2005037190A3 (en) Multiplex vaccines
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
EP1594536A4 (de) Adjuvante influenza-vakzine
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
TR200103574T2 (tr) Amid ikameli/katkılı imidazokinolinler
MXPA05014016A (es) Proteinas portadoras para vacunas.
DK1104306T3 (da) Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
WO2004030608A3 (en) Nanoemulsion vaccines
NZ532665A (en) Neisseria meningitidis antigens and compositions
BR9906927A (pt) Proteìnas de neisseria meningitidis
WO2003031464A3 (en) Remodeling and glycoconjugation of peptides
BR0210225A (pt) Holotoxina do cólera imunogênica mutante, composição imunogênica, método para realçar a resposta imune de um hospedeiro vertebrado a um antìgeno, sequência de dna isolada e purificada, molécula de ácido nucleico, célula hospedeira, método para produzir uma holotoxina do cólera imunogênica mutante, e, uso de uma holotoxina do cólera mutante
PL375398A1 (en) Immunostimulatory nucleic acids
MXPA04001224A (es) Agentes para incrementar la respuesta inmune.
DK1353689T3 (da) Immuniseringspræparater og anvendelse deraf
SG167667A1 (en) Nucleic acid compositions for stimulating immune responses
NO20063254L (no) Immunstimulerende sammensetning omfattende minst en toll-lignende reseptor 7 eller toll-lignende reseptor 8 agonist og en toll-lignende reseptor 4 agonist
DE60315827D1 (de) Verbesserte polysaccharid- und glykokonjugat-vakzine
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
AU8727201A (en) Genes involved in intestinal inflammatory diseases and use thereof

Legal Events

Date Code Title Description
8363 Opposition against the patent